← Leaderboards
Liron Bar-Peled
Massachusetts General Hospital
$4,230,233
Attributed
$4,914,465
Total exposure
6
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.1M · FY2017–25$2M$1.5M$1M$500K$0
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,914,465 · 6
By mechanism
R37$1,510,300 · 1
R01$1,368,465 · 1
R21$1,079,386 · 2
R00$726,814 · 1
K99$229,500 · 1
Top collaborators
- Brian Liau2 shared
Most similar at Massachusetts General Hospital
Same institution · by research overlap
- David E Fisher$28,420,496
- David Kc Cooper$22,744,194
- Salil Garg$2,483,170
- Raymond J Kelleher$9,450,163
- Jennifer A. Wargo$6,986,829
Others in their field
Other Emerging Leaders on “Cysteine”
- Aaron Gregory Schmidt · Boston Children'S Hospital$8,874,396
- Edward Thomas Chouchani · Dana-Farber Cancer Inst$7,891,829
- Gina Marie Denicola · H. Lee Moffitt Cancer Ctr & Res Inst$5,417,604
- Shannon Buckley · University Of Nebraska Medical Center$4,388,789
- Ming-Feng Tsai · University Of Colorado Denver$3,346,634
- Tomohiro Nakamura · Scripps Research Institute, The$3,323,369
Research focus
CysteineProteinsNext GenerationMalignant NeoplasmsMetabolicProteomicsTechnologyApplications GrantsTranscription FactorComplexGenetic TranscriptionOncogenicGrowthGenesSmall Molecule InhibitorCancer CellProtein FunctionAnti-Cancer TherapeuticGeneticCellsCancer Cell LineProliferatingLibrariesPharmacology
Grant awards (15)
Identification of Covalent Transcriptional Dependencies in Melanoma$670,836
R01 · FY2025 · CA · contact PI
Deciphering the Role of Reductive Stress in Non Small Cell Lung Cancer$384,300
R37 · FY2025 · CA · contact PI
Identification of Covalent Transcriptional Dependencies in Melanoma$697,629
R01 · FY2024 · CA · contact PI
Deciphering the Role of Reductive Stress in Non Small Cell Lung Cancer$365,086
R37 · FY2024 · CA · contact PI
Defining Nuclear H2O2 Regulation by Covalent Regulators$458,918
R21 · FY2023 · AG · contact PI
Deciphering the Role of Reductive Stress in Non Small Cell Lung Cancer$376,614
R37 · FY2023 · CA · contact PI
Chemical Proteomic Identification of Druggable Oncogenic Transcription Factors$192,424
R21 · FY2023 · CA · contact PI
Deciphering the Role of Reductive Stress in Non Small Cell Lung Cancer$384,300
R37 · FY2022 · CA · contact PI
Chemical Proteomic Identification of Druggable Oncogenic Transcription Factors$192,424
R21 · FY2022 · CA · contact PI
Mapping druggable co-dependency pathways in NRF2-driven lung cancers$249,000
R00 · FY2021 · CA · contact PI
Chemical Proteomic Identification of Druggable Oncogenic Transcription Factors$235,620
R21 · FY2021 · CA · contact PI
Mapping druggable co-dependency pathways in NRF2-driven lung cancers$228,814
R00 · FY2020 · CA · contact PI
Mapping druggable co-dependency pathways in NRF2-driven lung cancers$249,000
R00 · FY2019 · CA · contact PI
Mapping druggable co-dependency pathways in NRF2-driven lung cancers$114,750
K99 · FY2018 · CA · contact PI
Mapping druggable co-dependency pathways in NRF2-driven lung cancers$114,750
K99 · FY2017 · CA · contact PI